Skip to main content

Strengthening Medicare for Patients and Providers Act of 2023

The Medicare Physician Fee Schedule (MPFS) Conversion Factor has played a significant role in shaping the reimbursement rates for healthcare services provided by physicians under the Medicare program in the United States. The conversion factor is a crucial component of the MPFS, determining the dollar value assigned to the relative value units (RVUs) assigned to each medical service. This factor has undergone several changes over the years in response to evolving healthcare policies and financial considerations.

The history of the conversion factor dates back to the implementation of the Resource-Based Relative Value Scale (RBRVS) in 1992. The RBRVS system aimed to standardize physician payments based on the complexity and resource utilization of services provided. Over time, the conversion factor has seen several adjustments such as the creation (and elimination) of the sustainable growth rate formula and the more recent shift to quality payment programs and accountable care.

Under current law, beginning in 2026, the Medicare Physician Fee Schedule will be subject to two separate conversion factors depending on whether the physician participates in an alternative payment model (APM). For physicians who participate in an APM, the conversion factor is increased by 0.75% while for physicians not participating in an APM the conversion factor is increased by only 0.25%.

In addition, the current law does not allow for an inflation update to the Medicare payments for physician services. The SMPPA, if passed would normalize the increases across these two cohorts of physicians by applying an increase to the conversion factor equal to the MEI.

On April 3rd, Mr. Raul Ruiz (D-CA-25) and 13 cosponsors introduced yet another adjustment to the CF via the Strengthening Medicare for Patients and Providers Act of 2023 (SMPPA). This bill would replace the separate conversion factors for qualifying APM participants and other physicians with a single conversion factor and provides for an update that is equal to the annual percentage increase in the Medicare Economic Index, beginning in 2024. (The Medicare Economic Index is a specialized index that is generally used to determine allowed charges for physician services based on annual price changes.)


A number of stakeholders, including the AMA, American Academy of Neurology, American Academy of Family Physicians, American Academy of Cardiology, American College of Emergency Physicians, American College of Physicians, and the American Psychiatric Association co-signed a letter of support applauding the bill's efforts to “advances the ongoing need to provide financial stability to physician practices in order to preserve access to care for Medicare beneficiaries.”

While the Congressional Budget Office has yet to formally score this bill, and it is difficult to accurately estimate what impact this change could make, the AMA demonstrated that compared to inflation, Medicare payments to physicians decreased 26% since 2001. 

Legislators have struggled for decades to develop new tools that can be used to control growth in spending under the Physician Fee Schedule. This latest alternative has the potential to increase spending on physician-provided services. However with total spending on physician and clinical services approaching $865 billion in 2020, a 1% increase could drain Medicare coffers by an additional $8.6 billion -- without taking into account organic growth in service utilization and enrollment.



Comments

Popular posts from this blog

Innovative Models for Lowering Drug Spending

Recently, much has been written about the escalating costs of drug prices in the US. Increasing drug prices are present challenges to those who struggle with affordability and access to their medications. The Inflation Reduction Act brought changes to the way the Medicare program reimburses for prescription drugs. Last year, President Biden challenged the Center for Medicare and Medicaid Innovation (CMMI) to develop and test new payment models that can support value-based payments and promote high-quality healthcare. CMMI has recently proposed three models intended to improve affordability and access to drugs as well as measuring the feasibility of implementation.       1. The Medicare High-Value Drug List Model Under this model, Part D plans would be encouraged to offer a low, fixed co-payment across all cost-sharing phases of the Part D drug benefit for a standardized Medicare list of generic drugs that treat chronic conditions. Patients picking plans that participate in the Model wi

Bridging the Gap: The Long Road from FDA Approval to Medicare Coverage

A new study published in JAMA Health Forum reveals that the road to Medicare coverage for novel medical technologies is a long and winding one. Researchers found that only 44% of innovative devices and diagnostics approved by the FDA from 2016-2019 had even “nominal” Medicare coverage by 2022. This data highlights major hurdles in the system that delay patient access to beneficial emerging technologies. About the Research The study examined 281 novel products cleared through the FDA from 2016-2019 via the high-risk premarket approval, de novo, and breakthrough 510(k) pathways. These included things like groundbreaking diagnostic tests, implantable devices, and other innovative treatment technologies. The goal was to measure how long it took to establish national or regional Medicare coverage policies for these newly approved products. This is important because Medicare coverage is required before hospitals, physicians and patients can reliably access new technologies. Key Findings The

FDA Pilot Program for Certain In Vitro Diagnostic Tests

The U.S. Food and Drug Administration (FDA) has announced a pilot program designed to improve oncology patient care by establishing minimum performance standards for in vitro diagnostic tests (IVDTs) used with a limited number of oncology drug products. An IVDT is a device that provides critical information for the safe and effective use of a therapeutic product. The FDA typically requires a companion diagnostic to receive marketing authorization concurrently with the approval of the corresponding therapeutic product. However, in cases where no satisfactory alternative treatment exists for a serious or life-threatening condition, the FDA may approve a therapeutic product even without a companion IVDT. Currently, laboratory developed tests (LDTs) are being used in such cases, and the FDA exercises enforcement discretion regarding these tests. The pilot program aims to improve drug selection and patient care by establishing minimum performance characteristics for certain LDTs used in id